<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523480</url>
  </required_header>
  <id_info>
    <org_study_id>IRBSITE00000555</org_study_id>
    <secondary_id>20192539</secondary_id>
    <nct_id>NCT04523480</nct_id>
  </id_info>
  <brief_title>Testopel ® vs. Generic Testosterone Pellets.</brief_title>
  <official_title>Randomized Control Trial of Long Acting Subcutaneous Testosterone Pellets for Hypogonadism: Testopel ® vs. Generic Testosterone Pellets.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Empower Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate changes in vascular parameters in subjects receiving&#xD;
      Testopel 75mg (one time) versus subjects receiving Compounded Testosterone pellets 100mg (one&#xD;
      time) versus subjects receiving Compounded Testosterone pellets 200mg (one time) to&#xD;
      participant with clinical hypogonadism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypogonadism, or low testosterone (Low T), is the deficiency in producing testosterone by the&#xD;
      testes. Testosterone pellets is a long-acting formulation of TRT that is delivered&#xD;
      subcutaneously to men diagnosed with low T. Advantages to subcutaneous testosterone pellets&#xD;
      include ease of delivery and decreased risk of the medication being transfer upon skin&#xD;
      contact to woman or children. Long acting testosterone replacement Implantation of six to ≥10&#xD;
      testosterone pellets (450 to ≥750 mg) increased total testosterone into the therapeutic range&#xD;
      at 1 month post-implantation and sustained therapeutic levels (&gt;300) for 4-6 months.&#xD;
&#xD;
      Participants will be randomly assigned to 1 of 3 study groups. In one of the groups the&#xD;
      treatment will include implantation of Testopel ® 750mg (10 pellets with 75mg pellet) one&#xD;
      time, in the second group, treatment will include compounded subcutaneous testosterone 800mg&#xD;
      (8 pellets with 100mg pellet) one time and in the third group, treatment will include&#xD;
      compounded subcutaneous testosterone 800mg (4 pellets with 200mg pellet) one time.&#xD;
&#xD;
      The treatment takes approximately 30 minutes and will include: Clean and numb the insertion&#xD;
      site with lidocaine at 1%, followed by small incision in the skin, implantation of pellets&#xD;
      into subdermal fat layer and sealing the incision with Steri-strip. This is the current&#xD;
      standard of care of Testopel insertion and same procedure will be followed with both&#xD;
      compounded and commercial pellets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2020</start_date>
  <completion_date type="Anticipated">March 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Testosterone (T) levels</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Changes in serum Testosterone levels will be assessed in ng/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hematocrit (Hct) levels.</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Changes in serum Hct levels will be assessed in %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PSA levels</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change in serum Prostate Specific Antigen (PSA) levels will be assessed in ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estrogen levels</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change in serum estrogen levels will be assessed in pg/mL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testopel 75mg Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive a one-time subcutaneous testosterone insertion of 10 x 75 mg pellets of Testopel for a total of 750 mg Testopel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compounded testosterone pellets 100mg Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive a one-time subcutaneous testosterone insertion of 8 x 100 mg compounded testosterone for a total of 800 mg compounded testosterone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compounded Testosterone pellets 200mg Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive a one-time subcutaneous testosterone insertion of 4 x 200 mg compounded testosterone for a total of 800 mg compounded testosterone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testopel</intervention_name>
    <description>75 mg Testosterone pellets administered subcutaneously.</description>
    <arm_group_label>Testopel 75mg Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Pellet, 100Mg</intervention_name>
    <description>100 mg Testosterone pellets administered subcutaneously.</description>
    <arm_group_label>Compounded testosterone pellets 100mg Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Pellet, 200 Mg</intervention_name>
    <description>200 mg Testosterone pellets administered subcutaneously.</description>
    <arm_group_label>Compounded Testosterone pellets 200mg Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily sign and date the study consent form(s), which have been approved by an&#xD;
             Institutional Review Board (IRB). Written consent must be obtained prior to the&#xD;
             initiation of any study procedures.&#xD;
&#xD;
          -  Male between 18 and 75 years of age.&#xD;
&#xD;
          -  Documented diagnosis of primary hypogonadism (congenital or acquired) or&#xD;
             hypogonadotropic hypogonadism (congenital or acquired).&#xD;
&#xD;
          -  Serum total testosterone &lt; 300 ng/dL on 2 measurements&#xD;
&#xD;
          -  Naïve to androgen replacement or has discontinued current treatment and completed a&#xD;
             washout of 4 weeks following androgen treatment.&#xD;
&#xD;
          -  Judged to be in good general health as determined by the principal investigator based&#xD;
             upon the results of a medical history, physical examination, vital signs, laboratory&#xD;
             profile and a 12-lead electrocardiogram (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant sensitivity or allergy to androgens, or product excipients.&#xD;
&#xD;
          -  Clinically significant findings in the pre-study examinations including abnormal&#xD;
             breast examination requiring follow-up, abnormal ECG.&#xD;
&#xD;
          -  Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or&#xD;
             International Prostate Symptom Score (I-PSS) score &gt; 19 points.&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 40 kg/m2.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory value, in the opinion of the investigator,&#xD;
             in serum chemistry, hematology, or urinalysis including but not limited to:&#xD;
&#xD;
               1. Baseline hemoglobin &gt; 16 g/dL&#xD;
&#xD;
               2. Hematocrit &lt; 35% or &gt; 50%&#xD;
&#xD;
               3. PSA &gt; 4 ng/mL&#xD;
&#xD;
          -  History of seizures or convulsions, including febrile, alcohol or drug withdrawal&#xD;
             seizures.&#xD;
&#xD;
          -  History of any clinically significant illness, infection, or surgical procedure within&#xD;
             4 weeks prior to study drug administration.&#xD;
&#xD;
          -  History of stroke or myocardial infarction within the past 5 years.&#xD;
&#xD;
          -  History of, or current or suspected, prostate or breast cancer.&#xD;
&#xD;
          -  History of diagnosed, severe, untreated, obstructive sleep apnea.&#xD;
&#xD;
          -  History of abuse of alcohol or any drug substance in the opinion of the investigator&#xD;
             within the previous 2 years.&#xD;
&#xD;
          -  Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt&#xD;
             of a transfusion of any blood product within 12 weeks prior to the start of treatment.&#xD;
&#xD;
          -  Inadequate venous access for collection of serial blood samples required for&#xD;
             pharmacokinetic profiles.&#xD;
&#xD;
          -  Receipt of any investigational product within 4 weeks or within 5 half-lives prior to&#xD;
             the start of treatment.&#xD;
&#xD;
          -  Inability to understand and provide written informed consent for the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjith Ramasamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Molina, MD</last_name>
    <phone>3052434873</phone>
    <email>m.molina.leyba@miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Libert Ramos, A-PRN</last_name>
    <phone>305-243-4562</phone>
    <email>Libert.Ramos@miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami, Department of Urology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libert Ramos, A-PRN</last_name>
      <phone>305-243-4562</phone>
      <email>Libert.Ramos@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjith Ramasamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab. 2013 Aug;27(4):557-79. doi: 10.1016/j.beem.2013.05.002. Epub 2013 Jul 5. Review.</citation>
    <PMID>24054931</PMID>
  </reference>
  <reference>
    <citation>Walker WH. Testosterone signaling and the regulation of spermatogenesis. Spermatogenesis. 2011 Apr;1(2):116-120.</citation>
    <PMID>22319659</PMID>
  </reference>
  <reference>
    <citation>Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996 Dec;81(12):4358-65.</citation>
    <PMID>8954042</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 1987 Mar;106(3):354-61.</citation>
    <PMID>3544993</PMID>
  </reference>
  <reference>
    <citation>Jockenhövel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res. 1997 Jul 28;2(7):293-8.</citation>
    <PMID>9233903</PMID>
  </reference>
  <reference>
    <citation>Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf). 1994 Mar;40(3):341-9.</citation>
    <PMID>7514512</PMID>
  </reference>
  <reference>
    <citation>Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab. 1979 Jun;48(6):955-8.</citation>
    <PMID>447801</PMID>
  </reference>
  <reference>
    <citation>Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000 Aug;85(8):2670-7.</citation>
    <PMID>10946864</PMID>
  </reference>
  <reference>
    <citation>Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013 Aug 12;173(15):1465-6. doi: 10.1001/jamainternmed.2013.6895. Erratum in: JAMA Intern Med. 2013 Aug 12;173(15):1477.</citation>
    <PMID>23939517</PMID>
  </reference>
  <reference>
    <citation>Ullah MI, Riche DM, Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014 Jan 9;8:101-12. doi: 10.2147/DDDT.S43475. eCollection 2014. Review.</citation>
    <PMID>24470750</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Ranjith Ramasamy, MD</investigator_full_name>
    <investigator_title>Director of Male Fertility and Andrology, University of Miami</investigator_title>
  </responsible_party>
  <keyword>Low T</keyword>
  <keyword>Low Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

